Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they ...
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback